FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.
Function:
The protein encoded by the FRAT1 gene belongs to the GSK-3-binding protein family. The protein inhibits GSK-3-mediated phosphorylation of beta-catenin and also positively regulates the Wnt signaling pathway. It may play a role in tumor progression and in lymphomagenesis.
Subunit:
Binds DVL1. Binds GSK-3 and prevent GSK-3-dependent phosphorylation.
Subcellular Location:
Cytoplasmic.
Post-translational modifications:
Phosphorylated (By similarity).
Similarity:
Belongs to the GSK-3-binding protein family.
SWISS:
Q92837
Gene ID:
10023
Database links:
Entrez Gene: 10023 Human
Entrez Gene: 14296 Mouse
Omim: 602503 Human
SwissProt: Q92837 Human
SwissProt: P70339 Mouse
Unigene: 126057 Human
Unigene: 4573 Mouse
|
|
